Literature DB >> 26879463

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.

Ernst Ahlberg1, Alexander Amberg2, Lisa D Beilke3, David Bower4, Kevin P Cross4, Laura Custer5, Kevin A Ford6, Jacky Van Gompel7, James Harvey8, Masamitsu Honma9, Robert Jolly10, Elisabeth Joossens11, Raymond A Kemper12, Michelle Kenyon13, Naomi Kruhlak14, Lara Kuhnke15, Penny Leavitt5, Russell Naven13, Claire Neilan16, Donald P Quigley4, Dana Shuey16, Hans-Peter Spirkl2, Lidiya Stavitskaya14, Andrew Teasdale17, Angela White8, Joerg Wichard15, Craig Zwickl10, Glenn J Myatt18.   

Abstract

Statistical-based and expert rule-based models built using public domain mutagenicity knowledge and data are routinely used for computational (Q)SAR assessments of pharmaceutical impurities in line with the approach recommended in the ICH M7 guideline. Knowledge from proprietary corporate mutagenicity databases could be used to increase the predictive performance for selected chemical classes as well as expand the applicability domain of these (Q)SAR models. This paper outlines a mechanism for sharing knowledge without the release of proprietary data. Primary aromatic amine mutagenicity was selected as a case study because this chemical class is often encountered in pharmaceutical impurity analysis and mutagenicity of aromatic amines is currently difficult to predict. As part of this analysis, a series of aromatic amine substructures were defined and the number of mutagenic and non-mutagenic examples for each chemical substructure calculated across a series of public and proprietary mutagenicity databases. This information was pooled across all sources to identify structural classes that activate or deactivate aromatic amine mutagenicity. This structure activity knowledge, in combination with newly released primary aromatic amine data, was incorporated into Leadscope's expert rule-based and statistical-based (Q)SAR models where increased predictive performance was demonstrated.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (Q)SAR; Aromatic amines; ICH M7; Mutagenicity; Pharmaceutical impurities; SAR fingerprint

Mesh:

Substances:

Year:  2016        PMID: 26879463     DOI: 10.1016/j.yrtph.2016.02.003

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  11 in total

1.  Genetic toxicology in silico protocol.

Authors:  Catrin Hasselgren; Ernst Ahlberg; Yumi Akahori; Alexander Amberg; Lennart T Anger; Franck Atienzar; Scott Auerbach; Lisa Beilke; Phillip Bellion; Romualdo Benigni; Joel Bercu; Ewan D Booth; Dave Bower; Alessandro Brigo; Zoryana Cammerer; Mark T D Cronin; Ian Crooks; Kevin P Cross; Laura Custer; Krista Dobo; Tatyana Doktorova; David Faulkner; Kevin A Ford; Marie C Fortin; Markus Frericks; Samantha E Gad-McDonald; Nichola Gellatly; Helga Gerets; Véronique Gervais; Susanne Glowienke; Jacky Van Gompel; James S Harvey; Jedd Hillegass; Masamitsu Honma; Jui-Hua Hsieh; Chia-Wen Hsu; Tara S Barton-Maclaren; Candice Johnson; Robert Jolly; David Jones; Ray Kemper; Michelle O Kenyon; Naomi L Kruhlak; Sunil A Kulkarni; Klaus Kümmerer; Penny Leavitt; Scott Masten; Scott Miller; Chandrika Moudgal; Wolfgang Muster; Alexandre Paulino; Elena Lo Piparo; Mark Powley; Donald P Quigley; M Vijayaray Reddy; Andrea-Nicole Richarz; Benoit Schilter; Ronald D Snyder; Lidiya Stavitskaya; Reinhard Stidl; David T Szabo; Andrew Teasdale; Raymond R Tice; Alejandra Trejo-Martin; Anna Vuorinen; Brian A Wall; Pete Watts; Angela T White; Joerg Wichard; Kristine L Witt; Adam Woolley; David Woolley; Craig Zwickl; Glenn J Myatt
Journal:  Regul Toxicol Pharmacol       Date:  2019-06-11       Impact factor: 3.271

2.  Implementation of in silico toxicology protocols within a visual and interactive hazard assessment platform.

Authors:  Glenn J Myatt; Arianna Bassan; Dave Bower; Candice Johnson; Scott Miller; Manuela Pavan; Kevin P Cross
Journal:  Comput Toxicol       Date:  2021-10-28

3.  In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs.

Authors:  Raymond R Tice; Arianna Bassan; Alexander Amberg; Lennart T Anger; Marc A Beal; Phillip Bellion; Romualdo Benigni; Jeffrey Birmingham; Alessandro Brigo; Frank Bringezu; Lidia Ceriani; Ian Crooks; Kevin Cross; Rosalie Elespuru; David M Faulkner; Marie C Fortin; Paul Fowler; Markus Frericks; Helga H J Gerets; Gloria D Jahnke; David R Jones; Naomi L Kruhlak; Elena Lo Piparo; Juan Lopez-Belmonte; Amarjit Luniwal; Alice Luu; Federica Madia; Serena Manganelli; Balasubramanian Manickam; Jordi Mestres; Amy L Mihalchik-Burhans; Louise Neilson; Arun Pandiri; Manuela Pavan; Cynthia V Rider; John P Rooney; Alejandra Trejo-Martin; Karen H Watanabe-Sailor; Angela T White; David Woolley; Glenn J Myatt
Journal:  Comput Toxicol       Date:  2021-09-23

4.  Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.

Authors:  Curran Landry; Marlene T Kim; Naomi L Kruhlak; Kevin P Cross; Roustem Saiakhov; Suman Chakravarti; Lidiya Stavitskaya
Journal:  Regul Toxicol Pharmacol       Date:  2019-10-03       Impact factor: 3.271

5.  Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?

Authors:  Alexander Amberg; Lennart T Anger; Joel Bercu; David Bower; Kevin P Cross; Laura Custer; James S Harvey; Catrin Hasselgren; Masamitsu Honma; Candice Johnson; Robert Jolly; Michelle O Kenyon; Naomi L Kruhlak; Penny Leavitt; Donald P Quigley; Scott Miller; David Snodin; Lidiya Stavitskaya; Andrew Teasdale; Alejandra Trejo-Martin; Angela T White; Joerg Wichard; Glenn J Myatt
Journal:  Mutagenesis       Date:  2019-03-06       Impact factor: 3.000

6.  A cross-industry collaboration to assess if acute oral toxicity (Q)SAR models are fit-for-purpose for GHS classification and labelling.

Authors:  Joel Bercu; Melisa J Masuda-Herrera; Alejandra Trejo-Martin; Catrin Hasselgren; Jean Lord; Jessica Graham; Matthew Schmitz; Lawrence Milchak; Colin Owens; Surya Hari Lal; Richard Marchese Robinson; Sarah Whalley; Phillip Bellion; Anna Vuorinen; Kamila Gromek; William A Hawkins; Iris van de Gevel; Kathleen Vriens; Raymond Kemper; Russell Naven; Pierre Ferrer; Glenn J Myatt
Journal:  Regul Toxicol Pharmacol       Date:  2020-12-17       Impact factor: 3.271

7.  Predicting Aromatic Amine Mutagenicity with Confidence: A Case Study Using Conformal Prediction.

Authors:  Ulf Norinder; Glenn Myatt; Ernst Ahlberg
Journal:  Biomolecules       Date:  2018-08-29

Review 8.  Oxidation of Drugs during Drug Product Development: Problems and Solutions.

Authors:  Alen Gabrič; Žiga Hodnik; Stane Pajk
Journal:  Pharmaceutics       Date:  2022-01-29       Impact factor: 6.321

9.  Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project.

Authors:  Masamitsu Honma; Airi Kitazawa; Alex Cayley; Richard V Williams; Chris Barber; Thierry Hanser; Roustem Saiakhov; Suman Chakravarti; Glenn J Myatt; Kevin P Cross; Emilio Benfenati; Giuseppa Raitano; Ovanes Mekenyan; Petko Petkov; Cecilia Bossa; Romualdo Benigni; Chiara Laura Battistelli; Alessandro Giuliani; Olga Tcheremenskaia; Christine DeMeo; Ulf Norinder; Hiromi Koga; Ciloy Jose; Nina Jeliazkova; Nikolay Kochev; Vesselina Paskaleva; Chihae Yang; Pankaj R Daga; Robert D Clark; James Rathman
Journal:  Mutagenesis       Date:  2019-03-06       Impact factor: 3.000

10.  Management of pharmaceutical ICH M7 (Q)SAR predictions - The impact of model updates.

Authors:  Catrin Hasselgren; Joel Bercu; Alex Cayley; Kevin Cross; Susanne Glowienke; Naomi Kruhlak; Wolfgang Muster; John Nicolette; M Vijayaraj Reddy; Roustem Saiakhov; Krista Dobo
Journal:  Regul Toxicol Pharmacol       Date:  2020-10-13       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.